FDA — authorised 14 October 2011
- Application: NDA021825
- Marketing authorisation holder: CHIESI
- Local brand name: FERRIPROX
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Ferriprox® in United States
FDA authorised Ferriprox® on 14 October 2011
Marketing authorisations
FDA — authorised 29 March 2021
- Application: ANDA213239
- Marketing authorisation holder: HIKMA
- Local brand name: DEFERIPRONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 December 2025
- Application: ANDA220132
- Marketing authorisation holder: SENORES PHARMS
- Local brand name: DEFERIPRONE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Status: approved
Ferriprox® in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ferriprox® approved in United States?
Yes. FDA authorised it on 14 October 2011; FDA authorised it on 29 March 2021; FDA authorised it on 11 December 2025.
Who is the marketing authorisation holder for Ferriprox® in United States?
CHIESI holds the US marketing authorisation.